Free Trial

Medicenna Therapeutics (MDNA) Competitors

Medicenna Therapeutics logo
C$0.84 -0.02 (-2.33%)
As of 07/11/2025 03:53 PM Eastern

MDNA vs. FRX, ITH, IPA, CRDL, APM, GXE, GPH, WMD, EQ, and SGW

Should you be buying Medicenna Therapeutics stock or one of its competitors? The main competitors of Medicenna Therapeutics include Fennec Pharmaceuticals (FRX), International Tower Hill Mines (ITH), ImmunoPrecise Antibodies (IPA), Cardiol Therapeutics (CRDL), Andean Precious Metals (APM), Gear Energy (GXE), Graphite One (GPH), WeedMD (WMD), EQ (EQ), and Shoal Games (SGW). These companies are all part of the "pharmaceutical products" industry.

Medicenna Therapeutics vs. Its Competitors

Fennec Pharmaceuticals (TSE:FRX) and Medicenna Therapeutics (TSE:MDNA) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, analyst recommendations, earnings, valuation, institutional ownership, dividends, media sentiment and profitability.

Fennec Pharmaceuticals has a net margin of -2.30% compared to Medicenna Therapeutics' net margin of -533,640.00%. Fennec Pharmaceuticals' return on equity of 29.94% beat Medicenna Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Fennec Pharmaceuticals-2.30% 29.94% 8.88%
Medicenna Therapeutics -533,640.00%-159.88%-32.80%

Fennec Pharmaceuticals has a beta of 0.25, indicating that its share price is 75% less volatile than the S&P 500. Comparatively, Medicenna Therapeutics has a beta of 1.21, indicating that its share price is 21% more volatile than the S&P 500.

52.8% of Fennec Pharmaceuticals shares are held by institutional investors. Comparatively, 13.0% of Medicenna Therapeutics shares are held by institutional investors. 16.2% of Fennec Pharmaceuticals shares are held by insiders. Comparatively, 22.6% of Medicenna Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

In the previous week, Fennec Pharmaceuticals had 5 more articles in the media than Medicenna Therapeutics. MarketBeat recorded 5 mentions for Fennec Pharmaceuticals and 0 mentions for Medicenna Therapeutics. Fennec Pharmaceuticals' average media sentiment score of 0.04 beat Medicenna Therapeutics' score of 0.00 indicating that Fennec Pharmaceuticals is being referred to more favorably in the media.

Company Overall Sentiment
Fennec Pharmaceuticals Neutral
Medicenna Therapeutics Neutral

Fennec Pharmaceuticals has higher revenue and earnings than Medicenna Therapeutics. Fennec Pharmaceuticals is trading at a lower price-to-earnings ratio than Medicenna Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Fennec PharmaceuticalsC$34.86M6.69-C$800.44K-C$0.06-204.97
Medicenna TherapeuticsC$4.87K12,908.72-C$25.98M-C$0.36-2.31

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Fennec Pharmaceuticals
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
1 Strong Buy rating(s)
4.00
Medicenna Therapeutics
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

Summary

Fennec Pharmaceuticals beats Medicenna Therapeutics on 11 of the 15 factors compared between the two stocks.

Get Medicenna Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for MDNA and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding MDNA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of TSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

MDNA vs. The Competition

MetricMedicenna TherapeuticsBiotechnology IndustryMedical SectorTSE Exchange
Market CapC$62.85MC$129.37MC$5.61BC$6.20B
Dividend YieldN/A3.74%5.24%6.72%
P/E Ratio-2.313.4727.9650.47
Price / Sales12,908.724,141.03430.891,211.67
Price / Cash1.1513.1937.4683.29
Price / Book3.2242.088.044.70
Net Income-C$25.98M-C$92.15MC$3.18BC$301.20M
7 Day Performance-7.69%1.27%3.67%1.03%
1 Month Performance-8.70%4.30%4.09%4.02%
1 Year Performance-60.75%174.69%29.58%25.97%

Medicenna Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
MDNA
Medicenna Therapeutics
N/AC$0.84
-2.3%
N/A-55.8%C$62.85MC$4.87K-2.3120Gap Up
FRX
Fennec Pharmaceuticals
N/AC$11.69
+3.5%
N/A+36.0%C$225.44MC$34.86M-198.0310News Coverage
Gap Up
ITH
International Tower Hill Mines
N/AC$1.23
+5.1%
N/A+118.8%C$172.69MN/A-51.39220News Coverage
Gap Up
IPA
ImmunoPrecise Antibodies
N/AC$6.50
+0.8%
N/A+0.0%C$162.08MC$19.47M-7.3080News Coverage
Gap Down
CRDL
Cardiol Therapeutics
N/AC$1.92
+3.8%
N/A-36.8%C$159.32MN/A-3.7720
APM
Andean Precious Metals
2.3832 of 5 stars
C$1.29
+7.5%
C$2.00
+55.0%
+26.5%C$135.47MC$154.78M2.5530
GXE
Gear Energy
N/AN/AN/AN/AC$126.52MC$134.93M10.391,310
GPH
Graphite One
N/AC$0.69
-2.8%
N/A+4.5%C$69.87MN/A-9.9220
WMD
WeedMD
N/AC$0.28
-1.8%
N/A+0.0%C$67.82MC$27.53M-0.66628Gap Up
EQ
EQ
N/AC$0.97
flat
N/A-15.7%C$67.51MC$9.70M-14.4840Gap Down
SGW
Shoal Games
N/AC$0.50
+42.9%
N/A+0.0%C$65.56MC$106.98K-12.5040Gap Up

Related Companies and Tools


This page (TSE:MDNA) was last updated on 7/12/2025 by MarketBeat.com Staff
From Our Partners